ACN Newswire
Read More

Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding

indie
3 minutes

FREMONT, CA, Dec 14, 2022 - (ACN Newswire via SEAPRWire.com) - Verseon is delighted to announce that the European Journal of Medicinal Chemistry has published a paper (www.sciencedirect.com/science/article/abs/pii/S0223523422007577) describing the company's groundbreaking research that led to promising novel drug candidates for cardiovascular disease. Cardiovascular disease is the leading cause of death and disability in the world. Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms. However, currently prescribed so-called novel oral anticoagulants (NOACs) carry well-documented risks of major bleeds, which in many cases require hospitalization and can be life threatening. Developing drugs that prevent unwanted clots while preserving the body's ability to stop excessive bleeding is the "Holy Grail" of anticoagulant drug programs. Verseon is developing a new generation of anticoagulants called PROACs (Precision Oral Anticoagulants) that address this significant unmet medical need.The peer-reviewed paper documents how Verseon's medicinal chemistry team optimized variou...

ACN Newswire

AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share

indie
2 minutes

HONG KONG, Oct 5, 2022 - (ACN Newswire via SEAPRWire.com) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), today announced the allotment results of its Global Offering. The Offer Price is HK$16.16 per H share. Dealings in the H shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") are expected to commence on 6 October 2022 (Thursday) in board lot of 200 H shares each.The H shares initially offered under the International Offering were over-subscribed. The net proceeds from the Global Offering are intended for advancing R&D of vaccine candidates and continuing to enrich vaccine pipeline, funding the capital expenditure on the construction of new production facilities for new vaccine products, and investing in sales and marketing activities. The Company said, through one decade of organic growth and external resource integration, AIM Vaccine has become a major player in the Chinese vaccine industry. The official listing on the...

ACN Newswire
Read More

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

indie
12 minutes

HONG KONG, Sep 23, 2022 - (ACN Newswire via SEAPRWire.com) - AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.AIM Vaccine plans to offer an aggregate of 9,714,000 H shares (the "Offer Shares") under the Global Offering (subject to the Over-allotment Option), comprising an international offering (the "International Offering") of 8,742,400 H shares (subject to adjustment and the Over-allotment Option) and Hong Kong public offering (the "Hong Kong Public Offering") of 971,600 H shares (subject to adjustment), at an offer price of HK$16.16 per H share.The Hong Kong Public Offering will commence at 9:00 a.m. on 23 September 2022 (Friday) and close at 12:00 noon on 28 September 2022 (Wednesday) in Hong Kong. Dealings in H shares of the Company on SEHK are expected to commence at 9:00 a.m. on 6 October 2022 (Thursday), with the stock code 06660.HK in board lots of 200 H shares ...

ACN Newswire

Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

indie
10 minutes

HONG KONG, Mar 21, 2022 - (ACN Newswire via SEAPRWire.com) - The China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", stock code: 2179.HK, today announced the proposed listing of its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange"). Recbio plans to offer 30,854,500 H Shares (subject to the Over-allotment Option), of which 27,769,000 H Shares will be International Placing Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial Offer Shares; the remaining 3,085,500 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial Offer Shares. Recbio will open for Hong Kong Public Offering in Hong Kong at 9:00 a.m., 21 March 2022 (Monday), and close at 12:00 noon, 24 March 2022 (Thursday). Dealings in H Shares of Recbio on the Main Board of the Hong Kong Stock Exchange is expected to commence on 31 March 2022 (Thursday). The H Shares will be traded in board lot of 500 H Shares each. The Company's stock code is 2179.HK.-- Morgan Stanley Asia Limited, CMB International Capital Limited a...

ACN Newswire
Read More

Lepu Biopharma Co., Ltd. Successfully Listed on the Main Board of HKEX

indie
4 minutes

HONG KONG, Feb 23, 2022 - (ACN Newswire via SEAPRWire.com) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today, under the stock code of 2157 and in board lot of 1,000 H shares each. The share price of the Company closed at HK$7.14 per H share, with an intra-day high of HK$7.34 per H share. A total of approximately 15.8 million H shares were traded, with an aggregate turnover of approximately HK$112 million.Lepu Biopharma is listed on the main board of HKEX, with 126,876,000 H shares being offered globally, including 12,688,000 Hong Kong Offer Shares, 114,188,000 International Placing Shares. The net proceeds received are estimated at approximately HK$804.2 million from the Global Offering, after deduction of underwriting fees, commissions and other estimated expenses payable by the Company in connection with the Global Offering. The net proceeds are intended for funding the core products, funding the other key clinical-stage drug candidates and...

ACN Newswire

Sirnaomics Ltd. Announces Proposed Listing on the Main Board of SEHK

indie
8 minutes

HONG KONG, Dec 19, 2021 - (ACN Newswire via SEAPRWire.com) - Sirnaomics Ltd. ("Sirnaomics" or "Company", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company withs strong presence in both China and the U.S., today announces the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").Sirnaomics plans to offer an aggregate of 7,540,000 Offer Shares under the Global Offering (subject to the Over-allotment Option), consisting of 6,786,000 International Offer Shares (subject to reallocation and the Over-allotment Option) and 754,000 Hong Kong Offer Shares (subject to reallocation), at a price range between HK$65.90 and HK$72.70 per share.The Company will start its public offering in Hong Kong at 9 a.m. on December 20, 2021 (Monday) and end at 12 noon on December 23, 2021 (Thursday). Dealings in shares on SEHK are expected to commence on December 30, 2021 (Thursday), with the stock code of 2257.HK in board lots of 50 shares each.China International Capital Corporation Hong Kong Securities Limited is the Sole Sponsor, Joint Global Coordinator and Joint Bookrunner. The Hongkong and Shanghai Banking Corporation Limited, Nomura Int...

SeaPRwire

Crypto firms fight for top talent with hundreds of job openings

elean
4 minutes

SINGAPORE (BLOOMBERG) - Booming cryptocurrency firms say they're struggling to find the right candidates to fill hundreds of positions as a frenzy of interest in digital currencies and other assets pits them against some of the world's biggest financial institutions. Despite a rout in May, cryptocurrencies' total market value is up 400 per cent over the past year to about US$1.4 trillion (S$1.88 trillion), and traditional financial firms such as Goldman Sachs Group, Bank of New York Mellon and DBS Group Holdings are starting to offer services and trading. Meanwhile, the likes of CME Group are expanding crypto derivatives offerings - all of which is helping the asset class to mature. That's leaving fewer candidates for crypto firms who need dozens or hundreds of new workers to expand their business. Binance, the world's largest crypto exchange, is advertising for some 370 positions globally, according to its LinkedIn recruitment portal. New York-based Gemini plans to boost its Singapore headcount to 50 from 30 by December. Hong Kong-based Crypto.com, which employs more than 900 staff, has over 200 openings on its jobs page. "We are hiring aggressively," Binance chief executive offic...